🚀 VC round data is live in beta, check it out!
PYC Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for PYC Therapeutics and similar public comparables like Allergy Therapuetics, Akums Drugs and Pharma, Cullinan Therapeutics, Theravance and more.
PYC Therapeutics Overview
About PYC Therapeutics
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company’s drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
Founded
2001
HQ
Employees
5
Website
Sectors
Financials (LTM)
EV
$815M
PYC Therapeutics Financials
PYC Therapeutics reported last 12-month revenue of $6M and negative EBITDA of ($48M).
In the same LTM period, PYC Therapeutics generated $6M in gross profit, ($48M) in EBITDA losses, and had net loss of ($51M).
Revenue (LTM)
PYC Therapeutics P&L
In the most recent fiscal year, PYC Therapeutics reported revenue of — and net income of —.
PYC Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $6M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $6M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($48M) | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (760%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (804%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($51M) | XXX | — | XXX | XXX | XXX |
| Net Margin | (812%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
PYC Therapeutics Stock Performance
PYC Therapeutics has current market cap of $901M, and enterprise value of $815M.
Market Cap Evolution
PYC Therapeutics' stock price is $0.92.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $815M | $901M | 3.8% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPYC Therapeutics Valuation Multiples
PYC Therapeutics trades at 129.3x EV/Revenue multiple, and (17.0x) EV/EBITDA.
EV / Revenue (LTM)
PYC Therapeutics Financial Valuation Multiples
As of April 18, 2026, PYC Therapeutics has market cap of $901M and EV of $815M.
Equity research analysts estimate PYC Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PYC Therapeutics has a P/E ratio of (17.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $901M | XXX | $901M | XXX | XXX | XXX |
| EV (current) | $815M | XXX | $815M | XXX | XXX | XXX |
| EV/Revenue | 129.3x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (17.0x) | XXX | — | XXX | XXX | XXX |
| EV/EBIT | (16.1x) | XXX | — | XXX | XXX | XXX |
| EV/Gross Profit | 129.3x | XXX | — | XXX | XXX | XXX |
| P/E | (17.6x) | XXX | — | XXX | XXX | XXX |
| EV/FCF | (19.1x) | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PYC Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
PYC Therapeutics Margins & Growth Rates
PYC Therapeutics' revenue in the last 12 month declined by (43%).
PYC Therapeutics' rule of 40 is (2035%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PYC Therapeutics' rule of X is (2133%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
PYC Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (43%) | XXX | (39%) | XXX | XXX | XXX |
| EBITDA Margin | (760%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | 72% | XXX | 39% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (2035%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (2133%) | XXX | XXX | XXX |
| G&A Expenses to Revenue | 81% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1063% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
PYC Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| PYC Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Allergy Therapuetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Akums Drugs and Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Cullinan Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Theravance | XXX | XXX | XXX | XXX | XXX | XXX |
| SSY Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PYC Therapeutics M&A Activity
PYC Therapeutics acquired XXX companies to date.
Last acquisition by PYC Therapeutics was on XXXXXXXX, XXXXX. PYC Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by PYC Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPYC Therapeutics Investment Activity
PYC Therapeutics invested in XXX companies to date.
PYC Therapeutics made its latest investment on XXXXXXXX, XXXXX. PYC Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by PYC Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PYC Therapeutics
| When was PYC Therapeutics founded? | PYC Therapeutics was founded in 2001. |
| Where is PYC Therapeutics headquartered? | PYC Therapeutics is headquartered in Australia. |
| How many employees does PYC Therapeutics have? | As of today, PYC Therapeutics has over 5 employees. |
| Is PYC Therapeutics publicly listed? | Yes, PYC Therapeutics is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of PYC Therapeutics? | PYC Therapeutics trades under PYC ticker. |
| When did PYC Therapeutics go public? | PYC Therapeutics went public in 2005. |
| Who are competitors of PYC Therapeutics? | PYC Therapeutics main competitors are Allergy Therapuetics, Akums Drugs and Pharma, Cullinan Therapeutics, Theravance. |
| What is the current market cap of PYC Therapeutics? | PYC Therapeutics' current market cap is $901M. |
| What is the current revenue of PYC Therapeutics? | PYC Therapeutics' last 12 months revenue is $6M. |
| What is the current revenue growth of PYC Therapeutics? | PYC Therapeutics revenue growth (NTM/LTM) is (43%). |
| What is the current EV/Revenue multiple of PYC Therapeutics? | Current revenue multiple of PYC Therapeutics is 129.3x. |
| Is PYC Therapeutics profitable? | No, PYC Therapeutics is not profitable. |
| What is the current EBITDA of PYC Therapeutics? | PYC Therapeutics has negative EBITDA and is not profitable. |
| What is PYC Therapeutics' EBITDA margin? | PYC Therapeutics' last 12 months EBITDA margin is (760%). |
| What is the current EV/EBITDA multiple of PYC Therapeutics? | Current EBITDA multiple of PYC Therapeutics is (17.0x). |
| What is the current FCF of PYC Therapeutics? | PYC Therapeutics' last 12 months FCF is ($43M). |
| What is PYC Therapeutics' FCF margin? | PYC Therapeutics' last 12 months FCF margin is (678%). |
| What is the current EV/FCF multiple of PYC Therapeutics? | Current FCF multiple of PYC Therapeutics is (19.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.